



ABN 53 075 582 740

ASX ANNOUNCEMENT

15 November 2018

**EXECUTIVE CHAIRMAN APPOINTMENT –
MATERIAL CONTRACT TERMS**

Bionomics Limited (ASX: BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company announced on 9 November 2018 that Dr Errol De Souza would take up the role of Executive Chairman following the retirement of Dr Deborah Rathjen as Managing Director effective on 9 November 2018 and as CEO on 31 January 2019.

In recognition of these increased responsibilities, the Company has agreed the terms of

Dr De Souza's appointment, a summary of which are as follows:

Material Terms of Consultancy Agreement – Executive Chairman

In accordance with ASX Listing Rule 3.16.4, Bionomics makes the following disclosures in respect of the material terms of the Consulting Agreement between the Company and Dr Errol De Souza dated 15 November 2018:

Position	Executive Chairman
Commencement Date	12 November 2018
Expiry Date	31 March 2019
Fixed Remuneration	\$18,000 per month, for 10 working days per month
Short Term Incentive (STI)	Not applicable
Long Term Incentive (LTI)	Not applicable
Termination	7 days' notice by either party

FOR FURTHER INFORMATION PLEASE CONTACT:

Mr Jack Moschakis
Legal Counsel & Company Secretary
+61 8 8354 6181
jmoschakis@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of agitation, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.

www.bionomics.com.au